Academic Journal of Second Military Medical University (第二军医大学学报) 2015/36:12 PP.1374-1378
Objective To evaluate the clinical efficacy and safety of Kuanxionglifei Decoction combined with Sanziyangqin Decoction (KXLFD-SZYQD) in treating acute exacerbation of chronic obstructive pulmonary disease (AECOPD) with turbid phlegm obstructing lung syndrome, and to observe its effect on the lung function and routine blood tests. Methods Ninety patients meeting the diagnosis criteria were randomly divided into three groups. Thirty cases in KXLFD-SZYQD group were treated with western medicine and KXLFD-SZYQD, thirty cases in Kuanxionglifei Decoction (KXLFD) group were treated with KXLFD and western medicine, and thirty cases administered with western medicine alone were taken as controls. The therapeutic course was 7 d. The clinical therapeutic effects, accumulated scores of symptoms, pulmonary function and routine blood test were observed before and after treatment. Results (1) The total effective rates of KXLFD-SZYQD group, KXLFD group and control group were 93.3%(28/30), 80.0%(24/30) and 66.7%(20/30), respectively, with significant difference found between KXLFD-SZYQD group and control group (P=0.01). (2) The accumulated scores of symptoms showed that the improvement in KXLFD-SZYQD group was significantly greater than those in the other two groups (P=0.018, P=0.000), and the improvement of KXLFD group was significantly greater than that of the control group (P=0.027). (3) Compared with control group, KXLFD-SZYQD group also had significantly improved FEV1%, FEV1/FVC%, WBC and NEUT% (P=0.003, P=0.000, P=0.001,and P=0.003, respectively), and compared with KXLFD group, the improvement in KXLFD group was greater than that in the control group, but without significant difference (P=0.032, 0.037, 0.037,and 0.034, respectively). (4) The vital signs of the three groups were stable during the treatment, and there were no damage to the heart, liver or kidney and no other serious complications. Conclusion KXLFD-SZYQD combined with western medicine treatment can decrease WBC count and neutrophil percent, improve lung function and the clinical condition of AECOPD patients with turbid phlegm obstructing lung syndrome.
 The Global Initiative for Chronic Obstructive Disease Science Committee. Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease (revised 2100) [EB/OL]. [2015-02-20]. http://www.goldcopd.org/uploads/users/files/GOLD2011 Summary.pdf.
 中华人民共和国卫生部.中药新药临床研究指导原则(试行)[S]. 北京:中国医药科技出版社, 2002: 56-164.
 慢性阻塞性肺疾病急性加重(AECOPD)诊治专家组. 慢性阻塞性肺疾病急性加重(AECOPD)诊治中国专家共识(草案)[J].国际呼吸杂志, 2012, 32: 1681-1691.
 方邦江, 占 鸽. 宽胸理肺汤治疗慢性肺心病64例[J]. 陕西中医, 1994, 15: 150.
 郭 全, 方邦江, 陈宝瑾, 耿 赟. 宽胸理肺汤治疗慢性阻塞性肺疾病急性加重(痰浊壅肺证)临床研究[J]. 中国中医急症, 2013, 22: 1461-1465.
 段艳锋, 刘荃乐, 郑丹文, 吴晓新. 三拗汤和六君子汤、瓜蒌薤白半夏汤治疗急性加重期慢性阻塞性肺疾病疗效观察[J]. 新中医, 2014, 46: 43-44.
 李 倩, 粟 毅. 中性粒细胞在慢性阻塞性肺疾病发病中的作用[J]. 新医学, 2010, 41: 348-350.
 Lapperre T S, Willeras L N, Timeas W, Rabe K F, Hiemstra P S, Postma D S, et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD[J]. Chest, 2007, 131: 53-59.
 郎多勇, 孙志国, 李红兵, 杨文博, 杨卫东, 张新慧. 杏仁油对BABL/c小鼠抗炎镇痛作用的研究[J]. 时珍国医国药, 2012, 23: 1386-1388.
 王仁芳, 范令刚, 高文远, 张俊英. 桃仁化学成分与药理活性研究进展[J]. 现代药物与临床, 2010, 25: 426-429.
 张海涛, 张映铭, 王彩英, 方申存. 薤白提取物对哮喘豚鼠血清IL-6、TXB2及6-Keto-PGF1α的影响[J]. 放射免疫学杂志, 2012, 25: 154-156.
 季宗彬. 中药有效成分药理与应用[M]. 北京:人民卫生出版社, 2011: 374-375.
 Wise R A. The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression[J]. Am J Med, 2006, 119 (10 Suppl 1): 4-11.
 王艳宏, 王秋红, 夏永刚, 匡海学. 麻黄化学拆分组分的性味药理学评价--麻黄化学拆分组分"辛宣苦泄"平喘作用的研究[J]. 中国实验方剂学杂志, 2011, 17: 136-139.
 谭中英, 张锦红, 刘瑀曦, 潘丽洪, 张予阳, 刘晓秋. 薤白平喘作用有效部位的筛选研究[J]. 中国现代中药, 2011, 13: 40-41.
 刘金娜, 温春秀, 刘 铭, 贾东升, 杨太新, 谢晓亮. 瓜蒌的化学成分和药理活性研究进展[J]. 中药材, 2013, 36: 843-848.